William Blair just gave Vertex Pharmaceuticals a shiny bump in its 2025 earnings forecast, increasing EPS to $16.20 from ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Right now, a fantastic tariff safe-haven stock, one that's climbed nearly 70% in three years, is offering investors a great ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals took a confidence hit as Leerink Partners downgraded the stock from “strong-buy” to a mere “hold,” ...

Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.86%, which has investors questioning if this is right time to sell.

This was the stock's fourth consecutive day of losses.

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...